Mukdahan International Hospital Public Company (HANN) Fair Value & Analysis
Healthcare · TH · Market cap 510M THB
Fair value as of: Jun 24, 2026
Analysis
Mukdahan International Hospital Public Company (HANN) currently trades at 0.8800 THB, while our model-based Fair Value estimate is 0.7800 THB — implying the stock looks roughly 11.4% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Mukdahan International Hospital Public Company Limited operates hospitals in Thailand. The company operates Mukdahan International Hospital, Ruampat Yasothon Hospital, and Dr. Han Hospital. Its clinics and treatment centers include a physical therapy center, obstetrics and gynecology clinic, urology, pediatric clinic, accident and emergency center, family medicine clinic, general practice clinic, heart specialist clinic, and kidney center. The company also offers medical technology products, such as high-power laser therapy device; peripheral magnetic stimulation; and Fisioline Radiant, a radio frequency therapy device. In addition, it provides health checkup packages and programs comprising influenza vaccine, shingles vaccine, AVF/AVG prepaid package, hepatitis B vaccine package, Baby Love vaccine packages II and III, dengue vaccine package, endoscopy package, and pre-pregnancy health checkup program, as well as vaccine package to prevent hand, foot, and mouth disease. Further, the…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Mukdahan International Hospital Public Company (HANN) undervalued?
What is the fair value of HANN?
What is the quality score of HANN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.